Linear Pharma Private Limited
About Linear Pharma Private Limited
Data last updated:
Linear Pharma Private Limited is a private limited company based in Delhi, India. It operates in the real estate financing segment of the financial services sector. It was incorporated on 09 May 1988 and has been in existence for over 38 years.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U74899DL1988PTC031611. The company has 1 GST registration on record, which is no longer active.
The company has an authorised share capital of ₹40 Lakh and a paid-up capital of ₹37.37 Lakh. It is led by directors Devendra Singh and Kushal Singh.
Its last annual general meeting (AGM) was held on 30 September 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office is at Plot No – 1 G/F Lsc Institutional, Area Karkardooma, Delhi, India – 110092.
As per the financials filed for FY 2025, the company reported a revenue of ₹89,127, a growth of 6% compared to the previous year. For the same year it recorded a net profit of ₹46,895 (net margin 52.6%) and EBITDA of ₹66,653 (EBITDA margin 74.8%). Revenue has declined at a compounded annual rate (CAGR) of 47% over three years and 36% over five years.
The current compliance status is marked as compliant by the Registrar of Companies.
Company details
Contact details
Linear Pharma Private Limited's registered office is in Delhi, Delhi. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Registered AddressPlot No – 1 G/F Lsc Institutional, Area Karkardooma, Delhi, India – 110092
- IndustryFinancial Services, Real Estate Financing
To see the full contact details of Linear Pharma Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Financials of Linear Pharma Private Limited
FY 2024 filings availableLinear Pharma Private Limited reported revenue of ₹89,127 (up 6% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue rose 6% in the latest year, though over five years it has declined at a compounded annual rate (CAGR) of 36%. EBITDA rose 14% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹66,653 | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹46,895 | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 74.8% | ||||
| Net Profit Margin | 52.6% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Linear Pharma Private Limited, buy the company report.
Board of directors of Linear Pharma Private Limited
Linear Pharma has 2 current directors and 6 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Devendra Singh Also directs: Krita Consultants LLP, HBR Commodities Private Limited, Laudable Apparels Private Limited and 5 more | Director | 20 Sep 2012 | 14 Years 1 Months | Current |
| Kushal Singh Also directs: Krita Consultants LLP, P C Rice Mills Private Limited, HBR Commodities Private Limited and 5 more | Director | 01 Oct 2016 | 10 Years 1 Months | Current |
Auditor
Linear Pharma Private Limited is audited by A. K. Tayal and Associates for the financial year 2022.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| A. K. Tayal and Associates | FY 2022 | 011192N |
Shareholding
The shareholding of Linear Pharma Private Limited is on record for 5 financial years, the latest being FY 2021, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Linear Pharma Private Limited, buy the company report.
Legal cases
No court or tribunal cases involving Linear Pharma Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Linear Pharma Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Linear Pharma has 1 GST registration on record, and it has been cancelled or is inactive. Only active GST numbers are listed on this page.
To see the full GST registrations and return filing status of Linear Pharma Private Limited, buy the company report.
Recent activity
Linear Pharma Private Limited has 8 board changes on record since 2008: 2 appointments and 6 cessations. The latest: Ajay Kumar ceased to be Director on 01 Oct 2016.
Frequently asked questions
Linear Pharma is an active private limited company based in Delhi, India. The company works in real estate financing, within the financial services industry. It was incorporated on 09 May 1988 (38+ years old) and is registered under CIN U74899DL1988PTC031611.
Linear Pharma has 2 current directors:
- Devendra Singh - Director
- Kushal Singh - Director
The latest financial statements of Linear Pharma on record with the MCA are for the year ended 31 March 2024. Its last annual general meeting was held on 30 September 2024. Year-wise statements from 2015 are in the company report.
No. Linear Pharma has 1 GST registration on record and it is cancelled or inactive.
The CIN (Corporate Identification Number) of Linear Pharma is U74899DL1988PTC031611. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Linear Pharma was incorporated on 09 May 1988, making it 38+ years old. It is registered with the Registrar of Companies, Delhi.
Ajay Kumar ceased to be Director on 01 Oct 2016. Kushal Singh was appointed as Director on 01 Oct 2016. Harendra Singh Panwar ceased to be Director on 03 Oct 2012. Linear Pharma has 8 board changes on record in total.
The registered office of Linear Pharma is at Plot No – 1 GF Lsc Institutional, Area Karkardooma, Delhi, India – 110092.
Linear Pharma operates in the financial services industry, in the real estate financing segment.
The compliance status of Linear Pharma is compliant as of 24 August 2026. The company is actively filing with the Registrar of Companies.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
